Correvio Pharma (CORV)

[silkysullivan]

Size of European Market


The European market for drugs treating Atrial Fibrilation appears larger than the U.S.

Existing deals with Merck for Europe are enough to drive this stock price.

About Atrial Fibrillation

There are approximately 2.5 million Americans and 4.5 million Europeans that suffer from Atrial Fibrillation (AFib). Annual costs related to the management of AFib patients in the US and EU are estimated at $26 billion in total. Over the next 50 years, these costs are projected to increase significantly along with an expected 3 fold increase in the number of AFib sufferers.